August 22, 2025

Patient Awareness of Pharmacogenomic Testing Remains Low, ACS CAN Survey Reports

Less than half of responding patients with cancer were previously familiar with pharmacogenomic testing and its possible benefits, according to the results of a survey conducted by the American Cancer...

The ASCO Post

August 22, 2025

New Recommendations Released for Managing Aromatase Inhibitor–Induced Bone Loss

A group of experts from seven professional societies have published a joint position statement in the Journal of Bone Oncology on the management of aromatase inhibitor–associated bone loss as a guide ...

The ASCO Post

August 22, 2025

Nivolumab Plus Ipilimumab in mCRPC With an Immunogenic Signature

In a UK phase II trial (NEPTUNES) reported in the Journal of Clinical Oncology, Leone et al evaluated the efficacy of nivolumab plus ipilimumab in previously treated patients with immunogenic signatur...

The ASCO Post

August 22, 2025

Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

In a phase II study (ENGOT-OV60/GOG-3052/RAMP 201) reported in the Journal of Clinical Oncology, Banerjee et al evaluated the efficacy and safety of the RAF/MEK clamp avutometinib in combination with ...

The ASCO Post

August 18, 2025

Societies Issue Joint Updates to Hypertension Guidelines

A central update is the recommendation for use of the PREVENT calculator to help determine risk.

Conexiant

August 15, 2025

The Inflation Reduction Act and Ibrutinib

In August 2024, the Centers for Medicare & Medicaid Services (CMS) announced a negotiated price for the Bruton’s tyrosine kinase inhibitor ibrutinib that is 38% lower than the manufacturer’s list ...

The ASCO Post

August 14, 2025

Cannabis Use Disorder and Risk of Oral Cancer

Cannabis use disorder was associated with at least a threefold increase in the risk for developing oral cancer over 5 years compared with those without cannabis use disorder, according to findings fro...

The ASCO Post

August 13, 2025

Ozempic and Vision

Understanding recent updates to the risks associated with semaglutide

The Ophthalmologist

August 12, 2025

Exonate Initiates Phase IIb Trial of EXN407 for Diabetic Eye Disease

EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema

The Ophthalmologist